inupadenant
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 14, 2021 (NCT05117177)
Timeline
Indications
Mechanism of action
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[S@+]([O-])CCOc1cc(N2CCN(CCn3c(=O)sc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)c(F)cc1F- Mol. weight
- 604.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650331 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05403385 | Phase 2 | Aug 26, 2022 | iTeos Therapeutics |
| NCT05060432 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2021 | iTeos Therapeutics |
| NCT05117177 | Phase 1 | Jul 14, 2021 | iTeos Therapeutics, Université catholique de Louvain |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| iTeos Therapeutics | For profit | 3 | 3 | 2 | 2021 |
| Université catholique de Louvain | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1